Navigation Links
Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years

ntrolled study of 446 patients at 44 international sites is designed to assess the TAXUS moderate-release paclitaxel-eluting coronary stent system in reducing restenosis in high-risk patients, including de novo lesions with overlapping stents, lesions 26 mm or greater in length and small vessels. Lesion size ranged from 18 - 40 mm in length and 2.5 - 3.75 mm in diameter. TAXUS VI is the first randomized, controlled clinical trial to demonstrate durability of drug-eluting stents in complex lesions at four years. Follow-up included 98 percent of the patients enrolled at four years.

The study's results demonstrate a continued significant reduction in target lesion revascularization (TLR, or retreatment rate) as compared to the bare-metal stent control group at four years. The four-year TLR rate was 12.9 percent for the TAXUS Stent group, as compared with 21.4 percent for the control group (P=0.0082 (only two TLR events were reported between three and four years for the TAXUS Stent group)). The rate of patients living free of TLR events was 87.1 percent at four years for the TAXUS Stent group, as compared to 78.6 percent for the bare-metal stent control group.

The four-year results for TAXUS VI support long-term safety with the increased levels of paclitaxel in the moderate-release formulation used in the study. Even with an in vitro dosing rate 8-10 times greater than the commercialized slow-release formulation, no compromise in safety was observed. The TAXUS Stent group continues to report no new stent thrombosis after two years with a low 2.4 percent cardiac death rate.

Boston Scientific launched the slow-release formulation TAXUS Express2 paclitaxel-eluting coronary stent system in Europe and other international markets in 2003 and in the United States in 2004. The Company launched the slow-release formulation TAXUS(R) Liberte(TM) paclitaxel-eluting coronary stent system in Europe and other international markets in 2005. The TAXUS Express modera
'"/>




Page: 1 2 3

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
3. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
4. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... 2012  JARVIK HEART, Inc., a privately-held company that develops ... of its Pivotal Trial for evaluation of the Jarvik ... device for DT means that it will provide long-term, ... are not candidates for heart transplant. The approval permits ...
... Feb. 27, 2012 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited ... and marketer of medical devices worldwide, announced today its ... full year ended December 31, 2011. ... Fourth quarter net revenue increased 25.2% year-over-year ...
Cached Medicine Technology:JARVIK HEART Announces FDA Conditional Approval of Trial Using the Jarvik 2000® Heart for Destination Therapy 2JARVIK HEART Announces FDA Conditional Approval of Trial Using the Jarvik 2000® Heart for Destination Therapy 3Mindray Announces 2011 Fourth Quarter and Full Year Results 2Mindray Announces 2011 Fourth Quarter and Full Year Results 3Mindray Announces 2011 Fourth Quarter and Full Year Results 4Mindray Announces 2011 Fourth Quarter and Full Year Results 5Mindray Announces 2011 Fourth Quarter and Full Year Results 6Mindray Announces 2011 Fourth Quarter and Full Year Results 7Mindray Announces 2011 Fourth Quarter and Full Year Results 8Mindray Announces 2011 Fourth Quarter and Full Year Results 9Mindray Announces 2011 Fourth Quarter and Full Year Results 10Mindray Announces 2011 Fourth Quarter and Full Year Results 11Mindray Announces 2011 Fourth Quarter and Full Year Results 12Mindray Announces 2011 Fourth Quarter and Full Year Results 13Mindray Announces 2011 Fourth Quarter and Full Year Results 14Mindray Announces 2011 Fourth Quarter and Full Year Results 15Mindray Announces 2011 Fourth Quarter and Full Year Results 16Mindray Announces 2011 Fourth Quarter and Full Year Results 17
(Date:4/24/2014)... will bring together national experts to discuss solutions ... inaugural Brain Health Summit, titled "The Human Brain: ... Dr. Sandra Bond Chapman, founder and chief director ... Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) and ... Early Learning, U.S. Department of Education. The day ...
(Date:4/24/2014)... End-of-life aspects, the corresponding terminology, and the relevance ... considered in publications on randomized controlled trials (RCTs). ... the German Institute for Quality and Efficiency in ... as final report. , Together with external experts, ... examples: glioblastoma, lung cancer, malignant melanoma, and pancreatic ...
(Date:4/24/2014)... give than to receive at least if you,re an ... The study found that 15- and 16-year-olds who find pleasure ... members, are less likely to become depressed than those who ... money for themselves. , The researchers detail their findings in ... , The study focused on the ventral striatum, a brain ...
(Date:4/24/2014)... An Oregon State University researcher has found a relationship ... symptoms of autism spectrum disorder in very young children. ... first to show a direct relationship between motor skills ... gross motor skills should be included in treatment plans ... assistant professor in OSU,s College of Public Health and ...
(Date:4/24/2014)... by a scientist at the University of York reveals ... the development of the nervous system may also play ... A research team, led by Dr Will Brackenbury, ... Biology at York, has studied how voltage-gated sodium channels ... are found in the membranes of excitable cells, such ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2
... ... University Edwardsville School of Pharmacy has been awarded -- along with the Saint ... (NIH) grant to study ways of relieving chronic pain through new approaches in treating ... ...
... Kimberly-Clark Corporation (NYSE: KMB ) has joined forces ... performance of some of its product packaging. The new ... which benefit schools and communities nationwide. , Kimberly-Clark, ... health, hygiene, and well being, and TerraCycle are now ...
... Life ... , ... 2009 -- Life Care Centers of America recently named Michael Lops as its ... Care, succeeds Sharon Coleman in the position. His appointment is based on “his extensive experience ...
... , MONDAY, Nov. 2 (HealthDay News) -- Though someone ... lack basic knowledge about the potentially life-threatening disease, according ... , Diabetes is responsible for more deaths each year ... combined, but just 42 percent of those surveyed knew ...
... , ROCKVILLE, Md., Nov. 2 Vanda Pharmaceuticals Inc. (Vanda) ... development and commercialization of clinical-stage products for central nervous system ... quarter ended September 30, 2009. , Vanda reported ... of 2009, compared to $12.4 million for the second quarter ...
... , Preliminary evaluation after completion of ... endpoint has been met for patients with advanced-stage, ... Nov. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; ... company focused on endocrine therapy and oncology, today announced ...
Cached Medicine News:Health News:SIUE School of Pharmacy, SLU Pharmacology Receive $975K NIH Grant 2Health News:SIUE School of Pharmacy, SLU Pharmacology Receive $975K NIH Grant 3Health News:SIUE School of Pharmacy, SLU Pharmacology Receive $975K NIH Grant 4Health News:Kimberly-Clark & TerraCycle, Inc. Partner to Reduce Waste and Help Fund Schools and Non-Profits 2Health News:Kimberly-Clark & TerraCycle, Inc. Partner to Reduce Waste and Help Fund Schools and Non-Profits 3Health News:Lops named Life Care's New Chief Compliance Officer 2Health News:Americans Get Failing Grade on Diabetes Awareness 2Health News:Americans Get Failing Grade on Diabetes Awareness 3Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 2Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 3Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 4Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 5Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 6Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 7Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 8Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 9Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 10Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 11Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 12Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 2Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 3Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: